Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds
Novo Nordisk's Ozempic Reduces Smoking-Related Health Interventions In Diabetic Patients, Study Finds
A recent study published in Annals of Internal Medicine reveals that smokers with type 2 diabetes who are treated with Novo Nordisk A/S' (NYSE:NVO) Ozempic (semaglutide) show fewer tobacco-related medical interactions and interventions aimed at smoking cessation compared to those taking other diabetes medications.
近期在《內科醫學年鑑》上發表的一項研究顯示，接受諾和諾德公司（紐交所：NVO）的Ozempic（塞麥肽）治療的2型糖尿病患者，與服用其他糖尿病藥物的患者相比，菸草相關的醫療互動和戒菸干預會更少。
In the year following the initiation of Ozempic treatment, patients previously diagnosed with tobacco use disorder were up to 32% less likely to discuss tobacco use with their healthcare providers.
在開始使用Ozempic治療後的一年內，先前被診斷爲吸菸障礙的患者與他們的醫療保健提供者討論菸草使用的可能性會降低高達32％。
This reduction in discussions about tobacco use was observed even when compared to those taking other medications within the same class, known as GLP-1 receptor agonists.
即使與服用同類藥物-GLP-1受體激動劑的其他患者相比較，這種關於菸草使用的討論減少也會發生。
Also Read: UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages.
另外閱讀：英國國家醫療服務體系因服務短缺而少開重量減輕藥物Wegovy處方。
Additionally, Ozempic users were up to 68% less likely to receive prescriptions for smoking cessation medication and up to 21% less likely to receive smoking cessation counseling.
此外，使用Ozempic的用戶減少了高達68％的戒菸藥處方，並且降低了高達21％的接受戒菸諮詢的可能性。
The study compared 222,942 new users of antidiabetes medications, including 5,967 of semaglutide.
該研究比較了222,942名新用藥的抗糖尿病患者，其中包括5,967名服用塞麥肽。
Reuters notes that researchers highlighted the need for clinical trials to evaluate the potential of Ozempic's active ingredient, semaglutide, in smoking cessation.
路透社注意到，研究人員強調了需要進行臨床試驗來評估Ozempic的活性成分塞麥肽在戒菸方面的潛力。
The study, sponsored by the U.S. National Institutes of Health, suggests that semaglutide may reduce the desire to smoke by dampening the rewarding effects of nicotine in the brain.
由美國國立衛生研究院資助的這項研究建議，塞麥肽可能通過抑制大腦中尼古丁的獎勵效應來降低吸菸的慾望。
The research added that semaglutide was associated with reduced smoking cessation medication prescriptions and counseling.
該研究還指出，塞麥肽與減少戒菸藥和諮詢的相關性有關。
Similar findings were observed in patients with and without a diagnosis of obesity. For most group comparisons, the differences occurred within 30 days of prescription initiation.
在肥胖和非肥胖患者中均觀察到了類似的發現。對於大多數群體比較，差異發生在處方開始30天之內。
Despite the reduced tobacco disorder-related encounters, the study did not include data on whether patients stopped or decreased tobacco use after starting on the various drugs, the Reuters report added.
儘管減少了與菸草障礙有關的醫療互動，但研究沒有包括關於患者在使用各種藥物後是否停止或減少菸草使用的數據，據路透社報道。
While the observed reduction in medical interactions might suggest decreased tobacco use or relapses, researchers cautioned that it could also indicate a reduced willingness to seek help to quit smoking.
雖然觀察到醫療互動減少可能暗示着菸草使用減少或復發，但研究人員警告稱，這也可能表明減少了尋求戒菸幫助的意願。
Price Action: NVO stock closed at $127.97 on Monday.
股價走勢：NVO股票週一收盤價爲127.97美元。
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
免責聲明：本內容部分使用人工智能工具生成，並經Benzinga編輯審核發佈。
- Oral Weight Loss Drugs Vs. Injections – Pills Are Promising Yet Challenging Frontier.
- 口服減肥藥與注射減肥藥—藥片是一片充滿希望但具有挑戰性的前沿。
